AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development
Funding from SPRIND and Family Offices
AATec Medical GmbH (AATec), a biotech company developing a multi-product platform for the treatment of respiratory diseases based on recombinant alpha-1 antitrypsin (AAT), announced that it has secured EUR 4 million in a pre-series A financing from Germany’s Federal Agency for Disruptive Innovation (SPRIND) and high-net worth individuals investors, industry experts and single family offices.
The proceeds will be used to advance the development of ATL-105, AATec’s lead drug candidate in chronic respiratory inflammation and infectious respiratory diseases. ATL-105 will initially be developed for the treatment of non-cystic fibrosis bronchiectasis (NCFB), a chronic inflammatory respiratory disease without any causative therapies. Current NCFB treatment is limited to symptomatic therapy including antibiotics, macrolides, and physical therapy. The funding will support IND-enabling activities and position ATL-105 for entry into clinical trials by 2026.
Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, commented: “This funding is a crucial step toward preparing ATL-105 for clinical development. Non-CF bronchiectasis significantly impacts patients’ quality of life, and current treatment options are limited. We believe that ATL-105 has the potential to offer a meaningful therapeutic advance for millions of patients worldwide. In Western countries alone, more than 3 million patients suffer from NCFB. Thanks to our novel protein inhalation approach, ATL-105 is delivered directly to the lungs, maximizing therapeutic effectiveness at the primary site of inflammation and minimizing systemic side effects. The support from SPRIND validates our innovative approach and highlights the transformative potential of our technology.”
Sigrid Koeth, Innovation Manager at SPRIND, added: “At SPRIND, we’re looking for ideas that can fundamentally change things for the better. We believe that AATec’s approach using recombinant alpha-1 antitrypsin has great potential in a wide range of respiratory diseases and infections. Innovations like this can be key in protecting public health and strengthening the resilience of our healthcare systems.”
AATec Medical’s lead product candidate, ATL-105, is based on a novel recombinant alpha‑1 antitrypsin (AAT), a human serine protease inhibitor with broad anti-inflammatory, immunomodulatory and anti-infective properties. Robust preclinical proof-of-principle data demonstrate ATL-105’s excellent safety profile and broad therapeutic potential by effectively targeting key pathological processes in inflammatory lung diseases.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.